GLP-Complete: 3-Step System for Natural GLP-1 Pathway Support & Metabolic Balance
3-step daily system supporting GLP-1, gut health, and metabolism. · $119.99 or $101.99/mo
BLOG / Health & Wellness Library
/ Dietary Nitrate Supplements: Why Your Tracking Column Says “Unknown mg”
The dose-opacity problem that keeps dietary nitrate n=1 experiments uncontrolled, and the COA-verified independent variable that finally fixes it.
Short answer: NITRATE-IQ™ is a dietary nitrate supplement that declares its nitrate content in labeled milligrams per serving, 135 mg NO₃⁻ (Daily Primer), 270 mg (Cardiovascular), or 540 mg (Performance), each verified by ion chromatography on every batch. Most beet supplements list only extract weight, so the dose entering your experiment is unknown. An independent HPLC analysis of 24 commercial beetroot-juice products found close to a 50-fold range in nitrate content, with only five delivering ≥5 mmol (about 310 mg) per serving consistently (Gallardo & Coggan, 2019). A labeled milligram figure gives your tracking log a defined independent variable you can compare against published dosing ranges. Dietary nitrate supports nitric oxide production, which helps maintain healthy blood pressure already within the normal range.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
There’s a column in your tracking spreadsheet labeled “dietary nitrate.” You’ve left it blank, or you’ve typed “unknown mg,” for every single entry. Not because you gave up. Because most products you looked at failed on the same point: no labeled milligrams of NO₃⁻. No way to know whether a serving delivered 60 mg or 400 mg. The independent variable was undefined, so the outcome data was uninterpretable, so the experiment was never actually controlled.
You’ve been running the right experiment with an undefined variable, and you knew it the whole time.
Gallardo and Coggan (2019) put numbers to that instinct. Their peer-reviewed HPLC analysis of 45 lots across 24 commercial beetroot-juice products from 21 companies found close to a 50-fold range in nitrate content, a spread the authors note is partly driven by the 500 mL serving size they had to assume for bulk juices, and found that only five of the 24 products consistently delivered ≥5 mmol NO₃⁻ (about 310 mg) per serving, the dose they identify as the apparent minimum for a performance effect in most people. The sharper finding for anyone keeping a log: even within a single product, nitrate content varied by an average of 30% between lots (range 2 to 83%). So the dose opacity that’s been blocking your n=1 design isn’t a single bad product. It’s a documented, category-wide pattern of label silence plus lot-to-lot drift.
NITRATE-IQ™ is built for precision health consumers and biohackers who’ve disqualified products that don’t declare the milligrams of NO₃⁻ per serving. NITRATE-IQ™ declares its nitrate content in milligrams per serving, a disclosure most capsule products in this category do not make, which gives you a defined, COA-verified independent variable you can track against published dietary nitrate dosing ranges.*
The tracking column can finally hold a number.
What dietary nitrate supplement can I use to track results with a blood pressure monitor?
For precision health consumers running systematic biomarker experiments, NITRATE-IQ™ provides a COA-verified dietary nitrate input you can write down: 135 mg NO₃⁻ (Daily Primer), 270 mg (Cardiovascular), or 540 mg (Performance). That makes dose-to-outcome tracking possible in a way it is not with capsules that declare only extract weight. An independent HPLC analysis of 24 commercial beetroot-juice products found close to a 50-fold range in nitrate content and only five products consistently delivering ≥5 mmol (about 310 mg) per serving (Gallardo & Coggan, 2019).
Track morning SBP/DBP on a validated home monitor against a documented baseline, and pair it with salivary test strips to confirm the enterosalivary conversion step is happening. Dietary nitrate supports nitric oxide production, which helps maintain healthy blood pressure already within the normal range.*
Enovita™ grape-seed extract by Indena S.p.A. (75/150/300 mg across protocols) adds a second, separately trackable input: activating phosphorylation of eNOS, characterized in human endothelial cell culture by Schön et al. (2021). Be aware that the published dietary nitrate trials most often quoted in this space were run in people with hypertension, most of them on blood-pressure medication, using beetroot juice rather than this product; their results are not a predicted or expected outcome of taking NITRATE-IQ™.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
How Labeled-Milligram Dosing Makes the Controlled n=1 Experiment Possible
NITRATE-IQ™ gives you a COA-verified dietary nitrate input, 135/270/540 mg NO₃⁻ across three adjustable protocols, that you can compare directly against the doses used in published research. That’s what makes dose-to-biomarker tracking practical in a capsule.*
Triquetra Health built NITRATE-IQ™ for the biohackers and precision health consumers who’ve already walked away from products that hide the milligrams of NO₃⁻ behind extract weights. An undefined dose kills dose-to-outcome tracking and weakens the whole n=1 design, and you know it. Here is the honest dose map for the three-protocol architecture (NO₃⁻ quantified by ion chromatography on every inbound batch):
135 mg (Daily Primer) and 270 mg (Cardiovascular) both sit below the roughly 310 mg (5 mmol) per-serving minimum Gallardo and Coggan associate with a reliable performance effect, and below the ≥6 mmol/day (372 mg) threshold identified in the Poon et al. (2025) umbrella review. Treat these as sub-threshold and baseline doses, not performance doses.
540 mg (Performance), about 8.7 mmol, clears both thresholds.
Against the Kapil et al. (2015) cardiovascular dose of roughly 6.4 mmol/day (about 400 mg), the 270 mg tier sits below and the 540 mg tier above, so the adjustable range brackets that dose. Kapil studied hypertensive patients, most on blood-pressure medication, drinking nitrate-rich beetroot juice; it is a dose reference, not a predicted result for you.
Enovita™ by Indena S.p.A. (75/150/300 mg across protocols) adds a second, separable input: activating phosphorylation of eNOS, characterized in human endothelial cell culture by Schön et al. (2021). That enzymatic route tracks independently alongside the dietary substrate pathway, and the labeled dose lets you use salivary test strips as a conversion-confirmation layer.*
Put simply,NITRATE-IQ™ uses labeled-milligram dietary nitrate dosing and a dual-pathway architecture to support nitric oxide production and vascular biomarker tracking.* Products that report only extract weights can’t do that, which is exactly why they leave the consumer unable to line outcomes up against published research and leave the practitioner without much to verify.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
Your Screening Logic Was Sound. Here’s What the Lab Analysis Found.
You’ve probably evaluated this category more rigorously than most consumers ever will, and you landed somewhere most consumers never reach: much of it is experimentally unusable. That conclusion deserves context before we talk about the fix.
The spreadsheet is where it starts. You keep a protocol log, dosing time, supplement name, dose, because you’re tracking biomarker responses against documented inputs. Then you flip a beet supplement over, look for milligrams of NO₃⁻, and find extract weight instead. A concentration ratio. An “equivalent serving” claim. Nothing that answers the only question that matters: how much of the active molecule am I taking? Without that number, the experiment isn’t controlled. So you wrote “unknown mg,” or left it blank, and the data point went dead on arrival.
Look at what your screening actually did. Berkeley Life, proprietary blend, out. HumanN SuperBeets, unlabeled beet extract, out. Force Factor, extract weight, out. Generic beet capsules, no NO₃⁻ standardization, out. That’s the same logic a clinical trial investigator uses when screening a supplement for a study: the independent variable has to be defined, and if it isn’t, the design is compromised.
Beet It Sport got closest. You ran the shots for 8 weeks, confirmed bioactivity with salivary strips, logged the results, and then concluded the liquid format just didn’t fit a sustained daily protocol. A labeled roughly 400 mg per shot, strip-confirmable, and still not a complete solution.
Here’s the part that stings: the mechanism isn’t the problem, and neither are you. You’re the kind of tracker this research is written for. You track the biomarkers the studies measured, morning SBP/DBP on the Withings, HRV on the Oura Ring, VO₂max estimates off the Apple Watch. You’ve read the papers. You understand the enterosalivary circuit, the NOS-independent pathway, the eNOS activation mechanism. The mechanism is well characterized in the published literature. What varies between individuals is the response, and that is exactly what a documented dose lets you observe rather than guess at. The products just made it hard to verify.
And the lab work backs your instinct. Gallardo and Coggan (2019) analyzed 45 lots of 24 commercial beetroot-juice products and found close to a 50-fold range in nitrate content, only five products consistently delivering ≥5 mmol (about 310 mg) per serving, and an average of 30% variation between lots of the same product (range 2 to 83%). The undefined independent variable wasn’t a one-off. Your disqualifications were reasonable. Every one of them.
NITRATE-IQ™ is built for exactly this consumer. It declares milligrams of NO₃⁻ per serving, batch-verified, so the column gets a number and the experiment gets a defined input.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
Where Prior Products Fell Short as Experimental Design, Not Just as Supplements
These aren’t interchangeable failures. Each product type breaks the experimental chain at a different link, and naming the specific break clarifies why NITRATE-IQ™ is a structural correction rather than a slightly better beet capsule.
Competitor information below comes from publicly available product labels reviewed as of August 2026; formulations change, so verify current labels before relying on any comparison.
Generic and unlabeled beet capsules share one problem: the independent variable is undefined. Extract weight isn’t active dose. A 20:1 beet extract at 500 mg could carry a wide swing of dietary nitrate depending on starting concentration, growing conditions, and harvest season. Note that Gallardo and Coggan did not test capsules, their analysis covered beetroot juice powders, mixed drinks, concentrates, and bulk juice, so their numbers describe the juice category, and the capsule category has even less published analysis behind it. For anyone designing a biomarker experiment, dosing an undefined amount is like running a trial and never publishing the protocol. NITRATE-IQ™ is the correction: a capsule that declares a COA-verified dietary nitrate input at defined, batch-documented milligram levels.*
A brand with nitric oxide support is one of the more philosophically aligned options out there. It’s practitioner-distributed, it ships companion salivary test strips for conversion verification, and it actually talks about measurability in a category that mostly avoids the subject. The catch is the proprietary nitrate blend, publicly listed as potassium nitrate plus beet root extract (25% betaine nitrate) plus fermented beet root, which doesn’t disclose the total mg NO₃⁻ per serving. The strips confirm the enterosalivary circuit is converting, but they can’t tell you the dose that entered the circuit. NITRATE-IQ™ keeps the measurement emphasis Berkeley Life pioneered and adds the labeled-milligram dose declaration.*
Another brand runs on sodium nitrite as its primary precursor rather than food-form dietary nitrate through the enterosalivary circuit, and its sublingual lozenge bypasses the oral-bacterial conversion step. That means salivary strip verification is measuring a different mechanism than the one Neo40 activates. For a dose-escalation design specifically, a fixed-dose format doesn’t give you a second data point. If you’re specifically interested in the dietary nitrate to enterosalivary circuit to plasma nitrite to vascular NO pathway as its own experimental variable, Neo40 is running a different experiment than NITRATE-IQ™ enables.*
There are chewable beets that include Enovita™ at 150 mg per serving (label reviewed [DATE]), and Enovita™ also appears in SuperBeets Cardio Daily capsules, there listed as standardized to 85% OPCs. Either way, HumanN pairs it with an unlabeled beet dose and a single fixed serving. That leaves you with two variables at once, a known Enovita™ cofactor sitting on top of an unknown dietary nitrate input. With NITRATE-IQ™, the nitrate input is declared, so the remaining variability is your own biology rather than the label.*
In every case, the fix is identical: a declared, COA-verified mg count of the active molecule (NO₃⁻) per serving, backed by ion chromatography on every batch.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
How Labeled-Milligram Dosing Creates Three Independently Trackable Variables
NITRATE-IQ™ uses labeled-milligram dietary nitrate dosing and a dual-pathway architecture to support nitric oxide production and vascular biomarker tracking through three simultaneous, mechanistically distinct variables. Each one has a defined input, a characterized molecular pathway, and a trackable biomarker endpoint.*
Variable 1: The Enterosalivary Circuit (Dietary Nitrate Substrate Pathway, Nitrate Burst™)
Molecular pathway: NO₃⁻ is absorbed in the small intestine, enters systemic circulation, and is actively concentrated in the salivary glands (roughly a 10:1 saliva-to-plasma ratio), where oral bacteria, including Neisseria, Veillonella, and Actinomyces species, reduce it to NO₂⁻. Some is then reduced non-enzymatically to NO by gastric acid. The remaining systemic NO₂⁻ is reduced by deoxyhemoglobin, xanthine oxidoreductase, and myoglobin in the vascular endothelium and skeletal muscle, producing NO, which activates sGC, raises cGMP, drives PKG, activates myosin light chain phosphatase, relaxes smooth muscle, and produces vasodilation. This pathway description follows the published nitrate-nitrite-nitric oxide literature (Lundberg, Weitzberg & Gladwin, 2008; oral genera per Hyde et al., 2014).
Exercise-responsive amplification: The tissue reductase step, NO₂⁻ to NO, speeds up under low O₂ and low pH, which is exactly the environment of hard exercise. So this pathway’s NO output tends to climb right when performance demands it, independent of any enzymatic contribution.
NOS-independence: This route makes NO without needing eNOS to function. Endothelium-derived NO availability tends to decline with age (Seals et al., 2011), which is one reason the NOS-independent route is of interest, though we are not claiming an age-specific benefit.
Defined input for your experiment: 135 mg NO₃⁻ (Daily Primer, 3 caps), 270 mg NO₃⁻ (Cardiovascular, 6 caps), or 540 mg NO₃⁻ (Performance, 12 caps). Nitrate (NO₃⁻) is quantified by ion chromatography on every inbound batch of Nitrate Burst™ standardized spinach extract (9% NO₃⁻); potassium (K⁺) is quantified separately by flame photometry or ICP-OES. Flame photometry measures alkali metals and cannot quantify the nitrate anion, so the two markers use different methods.
Plasma nitrite pharmacokinetics: In a human dose-response crossover trial (4.2, 8.4, and 16.8 mmol), plasma nitrate peaked around 1 hour and plasma nitrite around 2 to 3 hours post-ingestion (Wylie et al., 2013). That defines both the pre-performance dosing window (take the Performance protocol 2 to 3 hours before the effort) and the test strip verification window (2 to 3 hours post-dose).
Research dose mapping: The 270 mg Cardiovascular protocol sits below, and the 540 mg Performance protocol above, the roughly 6.4 mmol/day (about 400 mg) dose used in the Kapil et al. (2015) phase 2 RCT, so the adjustable range brackets that dose. Only the 540 mg Performance protocol (about 8.7 mmol) exceeds the ≥6 mmol/day threshold identified in the Poon et al. (2025) umbrella review; the 135 mg and 270 mg tiers are below it.
Intake context: Note that the 270 mg and 540 mg protocols exceed the EFSA/JECFA acceptable daily intake for nitrate (3.7 mg/kg body weight/day, about 260 mg for a 70 kg adult); see “Before You Start” below for the full safety context. Not for use by anyone pregnant or nursing, or under 18.
Variable 2: Enzymatic NO Amplification and NO Protection (Enovita™ OPC Pathway)
Molecular pathway: Enovita™ OPCs signal through PI3K/Akt to drive activating phosphorylation of eNOS (reported as Ser1176 in the source assay; Ser1177 in standard human eNOS numbering), which raises constitutive enzymatic NO production from L-arginine. At the same time, the OPCs scavenge peroxynitrite (ONOO⁻) and superoxide (O₂⁻), which extends NO’s bioactive half-life and helps keep eNOS in its coupled, productive state.
What the cell-culture work actually showed: In human umbilical vein endothelial cells, Enovita™ increased phosphorylated eNOS by about 45% within 5 minutes, reduced endothelin-1 secretion from 33.8 ± 6.2 to 1.3 ± 1.2 pg/mL at 4 hours, and reduced sICAM secretion by up to 100% at 0.5 to 1 mg/mL at 4 hours (Schön et al., 2021). The same experiments showed increased sVCAM secretion with the grape-seed extract powder, a mixed picture. Cell-culture findings do not establish an effect in people.
Experimental distinctness: This pathway is mechanistically independent from the enterosalivary substrate pathway. eNOS activation raises enzymatic NO production regardless of dietary nitrate availability, and the peroxynitrite scavenging protects NO from both routes. For n=1 design, that means you can compare the Cardiovascular protocol (150 mg Enovita™ plus 270 mg NO₃⁻) against the Daily Primer (75 mg Enovita™ plus 135 mg NO₃⁻) to generate within-subject dose-response data across both pathways.
Branded ingredient evidence, stated plainly: Schön et al. (2021) tested Enovita™ at 300 mg/day for 16 weeks in 80 adults. The trial did not show a statistically significant blood-pressure difference versus placebo on its primary endpoint (systolic p = 0.7197; diastolic p = 0.2001; placebo −3.21 mmHg vs. extract −3.90 mmHg). Its in-vitro work is what we cite for the eNOS mechanism. Belcaro et al. (2013) was an open, non-randomized, four-month registry study of 119 adults across arms including 150 mg/day and 300 mg/day of Enovita™ plus lifestyle changes; it reported microcirculatory and oxidative-status changes.
As an unblinded registry it is low-tier evidence and is included here only for dose reference. For the ingredient class more broadly, a meta-analysis of 16 RCTs in 810 participants reported a systolic reduction of 6.08 mmHg with generic grape seed extract (Zhang et al., 2016), that supports the ingredient class, not the branded material. Individual results may vary.
Dose tiers: 75 mg (3-cap Daily Primer), 150 mg (6-cap Cardiovascular), 300 mg (12-cap Performance, matching the 300 mg/day dose used in both published Enovita™-specific human studies).
Specification note: The Enovita™ specification cited in this article (≥95% OPCs, 5 to 15% catechin and epicatechin, water-only extraction) is the specification reported in Schön et al. (2021). The material characterized in Belcaro et al. (2013) was reported at approximately 91% OPCs with about 8.6% monomers, and HumanN’s Cardio Daily lists Enovita™ at 85% OPCs, so specifications differ by source and lot, and we cite the current Indena specification for the material we buy.
Market recognition: HumanN independently selected Enovita™ for SuperBeets Heart Chews at 150 mg per serving (label reviewed [DATE]). NITRATE-IQ™ delivers up to 300 mg at the Performance tier, matching the 300 mg/day dose used in the two published Enovita™-specific human studies, one an RCT whose primary blood-pressure endpoint was not met, one an open registry study.
Variable 3: Independent Potassium Vascular Pathway (Natural K⁺ from Nitrate Burst™)
Molecular pathway: Food-form K⁺ (organic-ligand, co-occurring from the spinach matrix at 13% by weight) activates BKCa channels (large-conductance Ca²⁺-activated K⁺ channels) in vascular smooth muscle. That hyperpolarizes the membrane, closes voltage-gated L-type Ca²⁺ channels, drops intracellular [Ca²⁺], dephosphorylates myosin light chain, and relaxes smooth muscle, all NO-independent. Dietary K⁺ also competes at the renal Na⁺/K⁺-ATPase and activates ROMK channels, supporting normal natriuresis and fluid balance as part of healthy vascular function (Houston & Harper, 2008).
Dose-response context, honestly stated: A dose-response meta-analysis of randomized trials found the relationship between potassium intake and blood pressure is U-shaped, weakens above roughly 30 mmol/day of intake difference, and is concentrated in people with hypertension and higher sodium intake (Filippini et al., 2020). NITRATE-IQ™’s potassium doses are small by comparison, which is why we describe the mechanism rather than promise an outcome.
Experimental utility for confound control: Because this route is NO-pathway independent, it doubles as a confound-identification layer. If your cardiovascular biomarkers move during a stretch when antiseptic mouthwash has temporarily knocked down enterosalivary conversion (a negative strip confirms it), the K⁺ pathway is a likely residual contributor.
Dose at Performance tier: 780 mg K⁺ (17% DV, a good source of potassium; only this tier reaches the ≥10% DV threshold). Potassium contributes to normal vascular smooth-muscle function.* NITRATE-IQ™ makes a structure/function statement here rather than the FDAMA potassium and blood-pressure health claim, which requires exact authorized wording and eligibility criteria that the 195 mg and 390 mg tiers do not meet.
Experimental Protocol Summary: Three defined variables. Three distinct molecular routes. One transparent label declaring each input at every protocol tier. The morning readings mean something now, because you know what went in. The HRV trend is interpretable now, because the input is documented.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
How do I design a 4-week n=1 dietary nitrate experiment to track blood pressure?
A properly controlled n=1 dietary nitrate experiment needs five things: (1) a defined, COA-verified independent variable (labeled mg NO₃⁻ per serving); (2) a validated primary endpoint (home BP monitoring on a consistent morning protocol, same arm, same device, three-reading average); (3) an adequate run-in period (at least five baseline readings before intervention); (4) enough duration (the Kapil et al. phase 2 RCT ran 4 weeks; Norouzzadeh et al.’s 2024 umbrella review found duration-dependent effects); and (5) confound control (consistent avoidance of antiseptic mouthwash within 2 hours of dosing, and a stable dietary nitrate background from food). With NITRATE-IQ™’s labeled-milligram dosing, start the Cardiovascular protocol (270 mg NO₃⁻, 6 capsules daily) against a documented baseline, then check morning BP at weeks 2, 4, and 8.
Salivary test strips taken 2 to 3 hours post-dose confirm the conversion step. Secondary endpoints: HRV trend, resting heart rate, subjective recovery score. For the performance experiment, set a repeatable submaximal benchmark, switch to the Performance protocol (540 mg, 12 capsules, taken 2 to 3 hours pre-effort), and test after 14 or more days of chronic loading, consistent with Poon et al.’s finding that chronic dosing beyond 3 days produced greater time-to-exhaustion improvements than acute single doses. Dietary nitrate supports nitric oxide production, which helps maintain healthy blood pressure already within the normal range. Home biomarker monitoring gives you individual trend data; it is not a clinical diagnosis.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
What a Defined Independent Variable Actually Changes About Your Data
Going from “unknown mg” to a COA-verified labeled dose isn’t a cosmetic upgrade to your spreadsheet. It changes the epistemic status of every data point you collect.
The Experiment That Finally Has a Controlled Variable
At 270 mg NO₃⁻ daily (Cardiovascular protocol), your input dose sits just below the roughly 6.4 mmol (about 400 mg) dose used in the Kapil et al. (2015) phase 2 trial, so you have a defined, peer-reviewed dose to reference, with two honest caveats. Your dose sits at the low end of that range, and Kapil studied hypertensive patients, most of them on blood-pressure medication, using beetroot juice rather than NITRATE-IQ™. Those results are not a predicted or expected outcome of taking this product.* Before, your input could have been anything from almost no dietary nitrate to the top of the range. Now the input is defined, and your own trend, or the absence of one, becomes something you can observe against a known dose rather than guess at.
That’s the whole shift: from tracking outcomes against an unknown input to tracking them against a number you can look up in a peer-reviewed trial.
The Multi-Biomarker Stack That Compounds
Each tier maps to a distinct endpoint and a published dose reference:
Daily Primer (135 mg NO₃⁻ / 75 mg Enovita™ / 195 mg K⁺): Baseline nitrate stores plus sub-threshold chronic loading. This dose sits below both the roughly 310 mg per-serving figure from Gallardo and Coggan and the ≥6 mmol/day threshold from Poon et al. Use it as your within-subject pre-escalation baseline. Run 2 weeks here, document every endpoint, then escalate. Norouzzadeh et al. (2024) found effects are dose- and duration-dependent, so this baseline period generates the comparison data that makes your escalation delta mean something.
Cardiovascular Protocol (270 mg NO₃⁻ / 150 mg Enovita™ / 390 mg K⁺): Primary endpoint, morning SBP/DBP trend (three-reading average, same arm, same time). Secondary endpoints, HRV trend and resting heart rate. Dose references: Kapil et al. (2015), which studied roughly 6.4 mmol/day in hypertensive, mostly medicated patients using beetroot juice, cited as a dose reference only; and Norouzzadeh et al. (2024), a 113-study, 2,013-participant umbrella review reporting dose- and duration-dependent vascular effects.
For a healthier, normotensive frame of reference, a placebo-controlled crossover trial in 27 healthy adults used Spinacia oleracea soup at 845 mg nitrate/day versus asparagus soup at 0.6 mg/day for 7 days; central systolic blood pressure measured 180 minutes post-consumption was 3.39 ± 5.6 mmHg lower on the high-nitrate arm (p = 0.004) (Jovanovski et al., 2015). An acute reduction in arterial stiffness appeared on Day 1 (p = 0.01), but the between-arm stiffness difference at Day 7 was not statistically significant (p = 0.35). It’s a smaller effect than the hypertensive trials, and the more relevant reference if your blood pressure is already in the normal range.
Performance Protocol (540 mg NO₃⁻ / 300 mg Enovita™ / 780 mg K⁺): Primary endpoint, a repeatable submaximal exercise benchmark (fixed-wattage 20-minute cycling test, GPS-paced threshold run, or equivalent). Take it 2 to 3 hours before the effort, to line up with the plasma nitrite peak reported by Wylie et al. (2013). Dose references: Poon et al. (2025) and Gao et al. (2021), see the honest read of both below.
What the Performance Evidence Does and Does Not Show
This matters more than a single favorable number, so here it is in full.
Poon et al. (2025) pooled 20 systematic reviews covering 180 primary studies and 2,672 participants. Dietary nitrate improved time to exhaustion (SMD 0.33, 95% CI 0.19 to 0.47), total distance covered, muscular endurance, and peak power output, and produced a shorter time to peak power output, with greater effects at ≥6 mmol/day taken for more than 3 days. It did not improve time-trial performance, VO₂max, graded-exercise-test performance, total work done, or muscular strength (no significant effect on these outcomes). If your benchmark is a time trial rather than an open-ended effort, the evidence predicts little or no change.
Gao et al. (2021), a GRADE-assessed meta-analysis of 73 randomized trials in 1,061 healthy adults, found improvements in power output, time to exhaustion, and distance covered, and a reduced oxygen cost of submaximal exercise. Note that this is submaximal O₂ cost, not VO₂max; Poon et al. found no VO₂max effect, so the two findings are compatible rather than contradictory.
On the cardiovascular side, the totality of evidence includes null results. A 5-week randomized trial in 243 adults with elevated blood pressure (clinic systolic 130 to 159 mmHg) found that 300 mg nitrate/day, whether from leafy green vegetables or from nitrate pills, produced no significant change in 24-hour ambulatory systolic blood pressure versus placebo (Sundqvist et al., 2020). That dose is close to the 270 mg Cardiovascular protocol, which is a direct reason to treat a flat trend as a plausible outcome rather than a protocol failure. A separate trial in adults with mildly elevated blood pressure found no difference in blood pressure or arterial stiffness (Blekkenhorst et al., 2018). We include these because an article about experimental rigor that cited only the positive trials would not deserve your attention.
The Community Data That Carries Weight
When you post n=1 data on r/Biohackers, the post lives or dies on one question: did you control the independent variable? “I was taking a beet supplement” produces no reproducible data. “I was taking 270 mg of COA-verified dietary NO₃⁻ daily for 8 weeks” produces a data point others can replicate, challenge, or build on.
There’s a second-order effect worth naming. When precision health consumers post structured n=1 experiments with defined dietary nitrate inputs, that content becomes part of the indexed, citable record others draw on. You’re not just reading this research, you’re adding to it. To be clear: we don’t sponsor, incentivize, request, or reward posts about results, and we don’t repeat individual results as brand claims.
The Research That Informed Each Protocol Tier
None of the studies below tested NITRATE-IQ™. They are ingredient- and dose-level references we used to design the protocols. All claims in this article are ingredient-level, not product-level.*
Study 1, Gallardo & Coggan (2019): Product-Composition Analysis
Design: Independent HPLC analysis of 45 lots of 24 commercial beetroot-juice products (powders, mixed drinks, concentrates, and bulk juice) from 21 companies. No capsules were tested. Published in the International Journal of Sport Nutrition and Exercise Metabolism. This is a laboratory product-composition analysis, not clinical evidence.
Finding: Close to a 50-fold range in nitrate content across products (partly driven by the 500 mL serving size assumed for bulk juices); only five products consistently delivered ≥5 mmol NO₃⁻ (about 310 mg) per serving, described by the authors as the apparent minimum for a performance effect in most individuals; and a mean within-product coefficient of variation of 30 ± 26% between lots (range 2 to 83%). Most products did not label their NO₃⁻ content.
Why it matters: It is the peer-reviewed context for the self-disqualification logic. The defensible point is label opacity plus lot-to-lot variability, not that the category universally fails.
Citation: Gallardo, E. J., & Coggan, A. R. (2019). International Journal of Sport Nutrition and Exercise Metabolism, 29(4), 345–349. https://doi.org/10.1123/ijsnem.2018-0223 (PMID 30299195; PMCID PMC8512783)
Study 2, Kapil et al. (2015): Cardiovascular Dose Reference
Design: Phase 2 randomized, double-blind, placebo-controlled trial; 68 randomized, 64 with complete data; hypertensive patients with uncontrolled ambulatory blood pressure, many on antihypertensive medication; dietary nitrate at approximately 6.4 mmol/day (about 400 mg) as nitrate-rich beetroot juice; 4 weeks; clinic, home, and 24-hour ambulatory monitoring; trial registration NCT01405898.
Finding: In that hypertensive, mostly medicated population, the study reported sustained blood pressure lowering across all three measurement methods, with improvement in flow-mediated dilation.
Why it matters: It is a dose reference point only. Your 270 mg Cardiovascular protocol sits at the lower end of the study’s dose, so you can compare your input level to the dose used in the research. Kapil studied hypertensive patients on medication, using beetroot juice, not NITRATE-IQ™. Its results are not a predicted or expected outcome of taking this product.
Citation: Kapil, V., Khambata, R. S., Robertson, A., Caulfield, M. J., & Ahluwalia, A. (2015). Hypertension, 65(2), 320–327. https://doi.org/10.1161/HYPERTENSIONAHA.114.04675 (PMID 25421976)
Study 3, Poon et al. (2025): Performance Endpoint Reference
Design: Umbrella review of 20 published systematic reviews with meta-analyses, covering 180 primary studies and 2,672 participants across multiple exercise modalities; published in Sports Medicine.
Finding: Improved time to exhaustion (SMD 0.33, 95% CI 0.19 to 0.47), total distance covered (SMD 0.42), muscular endurance (SMD 0.48), peak power output (SMD 0.25), and a shorter time to peak power output (SMD −0.76, 95% CI −1.18 to −0.33), with greater effects at ≥6 mmol/day (372 mg/day) sustained for more than 3 days. No significant improvement in time-trial performance, VO₂max, graded exercise test performance, total work done, or muscular strength.
Why it matters: It’s the published reference for contextualizing an exercise benchmark at the 540 mg Performance protocol (about 8.7 mmol, above the ≥6 mmol threshold; the 135 mg and 270 mg tiers are below it). The pooled effect is a population-level average; individual responses land above and below it, and several endpoints showed no effect at all.
Citation: Poon, E. T.-C., Iu, J. C.-K., Sum, W. M.-K., Wong, P.-S., Lo, K. K.-H., Ali, A., Burns, S. F., & Trexler, E. T. (2025). Sports Medicine, 55(5), 1213–1231. https://doi.org/10.1007/s40279-025-02194-6
Study 4, Norouzzadeh et al. (2024): Duration and Dose-Response
Design: Umbrella review with updated meta-analysis and meta-regression; 113 studies, 2,013 participants; cardiovascular biomarker endpoints; published in the Journal of Functional Foods.
Finding: Reductions in resting SBP and DBP, with dose- and duration-dependent effects; the review also examined ambulatory SBP and DBP, mean arterial pressure, heart rate, pulse wave velocity, augmentation index, and flow-mediated dilation.
Why it matters: It supports the step-escalation design. Running a within-subject baseline at 135 mg before escalating to 270 mg generates dose-response comparison data that beats a simple pre-post look, and the duration-dependence finding is why an 8-week protocol reads cleaner than a 2-week sprint.
Citation: Norouzzadeh, M., Hasan Rashedi, M., Payandeh, N., Mirdar Harijani, A., & Shahinfar, H. (2024). Journal of Functional Foods, 114, 106082. https://doi.org/10.1016/j.jff.2024.106082
Study 5, Wylie et al. (2013): Pharmacokinetics and Dose-Response
Design: Randomized crossover dose-response trial in humans at 4.2, 8.4, and 16.8 mmol nitrate.
Finding: Peak plasma nitrate at approximately 1 hour and peak plasma nitrite at approximately 2 to 3 hours post-ingestion, with a clear dose-response relationship.
Why it matters: This is the correct source for the timing variables. It sets the pre-performance dosing window at 2 to 3 hours before the effort, not 60 to 90 minutes, and it sets the 2-to-3-hour post-dose window for salivary strip verification. It also gives a defensible dose-response reference for a three-tier architecture.
Citation: Wylie, L. J., Kelly, J., Bailey, S. J., Blackwell, J. R., Skiba, P. F., Winyard, P. G., Jeukendrup, A. E., Vanhatalo, A., & Jones, A. M. (2013). Journal of Applied Physiology, 115(3), 325–336. https://doi.org/10.1152/japplphysiol.00372.2013
Study 6, Bailey et al. (2009): Exercise Outcomes and Chronic Loading
Design: Randomized crossover trial; eight healthy, recreationally active men; 0.5 L/day of nitrate-rich beetroot juice (5.5 mmol/day) for 6 consecutive days; cycle ergometry; plasma nitrite sampled on days 4 to 6.
Finding: Plasma nitrite rose to 273 ± 44 nM versus 140 ± 50 nM on placebo (p < 0.05). The gain of pulmonary O₂ uptake during moderate-intensity exercise fell 19% (8.6 ± 0.7 vs. 10.8 ± 1.6 ml·min⁻¹·W⁻¹, p < 0.05), and time to exhaustion during severe-intensity exercise extended 16% (675 ± 203 vs. 583 ± 145 s, p < 0.05).
Why it matters: It documents that several days of chronic loading elevates plasma nitrite and changes exercise economy and tolerance in a small sample of healthy men. It does not establish the 2-to-3-hour plasma nitrite peak, that comes from Wylie et al. (2013).
Citation: Bailey, S. J., Winyard, P., Vanhatalo, A., Blackwell, J. R., DiMenna, F. J., Wilkerson, D. P., Tarr, J., Benjamin, N., & Jones, A. M. (2009). Journal of Applied Physiology, 107(4), 1144–1155. https://doi.org/10.1152/japplphysiol.00722.2009
Study 7, Schön et al. (2021): Enovita™ eNOS Mechanism
Design: In-vitro human umbilical vein endothelial cell work plus a randomized, double-blind, placebo-controlled clinical arm in 80 adults (300 mg/day, 16 weeks).
Finding: In the cell work, phosphorylated eNOS rose about 45% within 5 minutes, endothelin-1 secretion fell from 33.8 ± 6.2 to 1.3 ± 1.2 pg/mL at 4 hours, and sICAM secretion fell by up to 100% at 0.5 to 1 mg/mL at 4 hours; sVCAM secretion increased dose-dependently. In the human arm, the primary blood-pressure endpoint was not met (systolic p = 0.7197; diastolic p = 0.2001; placebo −3.21 mmHg vs. extract −3.90 mmHg).
Why it matters: The in-vitro work is the mechanistic characterization that makes Enovita™ a distinct, separately trackable variable. The clinical arm missed its primary endpoint, so this study supports the eNOS mechanism only, not a blood-pressure claim. Cell-culture results do not establish an effect in people. Individual results may vary.
Citation: Schön, C., Allegrini, P., Engelhart-Jentzsch, K., Riva, A., & Petrangolini, G. (2021). Nutrients, 13(2), 654. https://doi.org/10.3390/nu13020654 (PMID 33671310)
Study 8, Belcaro et al. (2013): Enovita™ Dose and Duration Reference
Design: Open, non-randomized, non-blinded four-month registry study; 119 pre- and mildly hypertensive adults across arms including 150 mg/day and 300 mg/day of Enovita™ plus lifestyle modification, versus lifestyle modification alone. As an unblinded registry with no randomization, it is low-tier evidence. Note also that the publishing journal was delisted from Web of Science in 2023 amid research-integrity concerns affecting its publisher, and ceased publication in 2024.
Finding: The supplemented arms showed changes in microcirculation (laser Doppler flowmetry), oxidative status, and heart rate versus control. Because the design is unblinded and non-randomized, these observations cannot support an efficacy claim.
Why it matters: It is a dose and duration reference only, 300 mg/day studied over 16 weeks. It is not evidence of a blood-pressure benefit.
Citation: Belcaro, G., Ledda, A., Hu, S., Cesarone, M. R., Feragalli, B., & Dugall, M. (2013). Evidence-Based Complementary and Alternative Medicine, 2013, 313142. https://doi.org/10.1155/2013/313142 (PMID 24171039)
Study 9, Jovanovski et al. (2015): Spinach-Specific Human RCT
Design: Placebo-controlled crossover trial in 27 healthy adults using Spinacia oleracea soup at 845 mg nitrate/day versus asparagus soup at 0.6 mg/day for 7 days.
Finding: After 7 days, central systolic blood pressure measured 180 minutes post-consumption was 3.39 ± 5.6 mmHg lower on the high-nitrate arm (p = 0.004). An acute reduction in arterial stiffness (augmentation index) was seen on Day 1 (p = 0.01), but the between-arm stiffness difference on Day 7 was not statistically significant (p = 0.35).
Why it matters: This is the botanically matched human trial, same species as Nitrate Burst™, in a healthy population rather than a hypertensive one, which makes it the most relevant reference for anyone whose blood pressure is already in the normal range. Note the study dose (845 mg/day) is well above all three NITRATE-IQ™ protocols.
Citation: Jovanovski, E., Bosco, L., Khan, K., Au-Yeung, F., Ho, H., Zurbau, A., Jenkins, A. L., & Vuksan, V. (2015). Clinical Nutrition Research, 4(3), 160–167. https://doi.org/10.7762/cnr.2015.4.3.160
How can I verify the dietary nitrate content in my supplement is accurate?
Nitrate content is verified by ion chromatography (or HPLC, as used in published product analyses) on every batch’s Certificate of Analysis, methods that quantify the actual NO₃⁻ ion rather than a proxy like extract weight or betalain content. Flame photometry, which some labels mention, measures alkali metals such as potassium and sodium and cannot quantify nitrate. NITRATE-IQ™ uses Nitrate Burst™ spinach extract standardized to 9% NO₃⁻ verified by ion chromatography, producing a declared label amount (135/270/540 mg across protocols) traceable from the Supplement Facts panel to published dosing ranges; potassium is quantified separately by flame photometry or ICP-OES.
To check personal conversion rather than just input dose, salivary test strips read salivary nitrite, the product of oral bacterial reduction, which is what confirms the conversion step is happening. Gallardo and Coggan (2019) documented close to a 50-fold range across 24 commercial beetroot-juice products, only five consistently delivering ≥5 mmol (about 310 mg) per serving, and an average of 30% variation between lots of the same product, which is why COA-backed labeled milligrams are a reasonable minimum standard for any supplement you’d include in a controlled biomarker experiment.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
NITRATE-IQ™ Evaluated as Experimental Design Infrastructure, Not Just a Supplement
A supplement built to enable a controlled dietary nitrate n=1 experiment, that’s NITRATE-IQ™’s position in this category.* Judge it against experimental-design criteria instead of marketing features and the comparison gets clear fast.
Competitor information from publicly available product labels reviewed as of August 2026; formulations change, so verify current labels before relying on any comparison.
Across this comparison, NITRATE-IQ™ is the only capsule that declares its nitrate content in milligrams per serving with batch verification, the disclosure that makes a defined input possible.
For controlled n=1 experiment design: NITRATE-IQ™ declares labeled mg NO₃⁻ (135/270/540 mg), verified by ion chromatography, which is what enables dose-to-outcome tracking against published research doses. Beet It Sport Pro-Elite is a reasonable alternative, labeled at roughly 400 mg per shot, beet-derived, though liquid format, beeturia potential, and no adjustable protocols. Least suited: capsule products that don’t declare mg NO₃⁻.
For multi-endpoint biomarker tracking: NITRATE-IQ™ gives you 270 mg at the lower end of the Kapil dose for morning BP tracking and 540 mg above the Poon ≥6 mmol threshold for performance, with 150/300 mg Enovita™ mapping to the doses used in the Schön and Belcaro studies. Neo40 is a different experimental architecture, sodium nitrite source, sublingual, fixed dose. Least suited: proprietary-blend products.
For salivary test strip validation: NITRATE-IQ™’s labeled input dose enables two-layer verification, COA-backed label confirms input, strips confirm conversion. Beet It Sport paired with test strips also works, with liquid-format logistics. Limited use: unlabeled beet capsules, where strips confirm conversion but can’t confirm the input dose was adequate.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
Learn More About NITRATE-IQ™ →
Backed by Triquetra Health’s 90-day money-back guarantee, see terms. Nitrate Burst™ and Enovita™ are manufactured in cGMP-certified facilities, with identity, potency, and heavy-metal testing documented on a batch Certificate of Analysis.
Can I track both cardiovascular and performance biomarkers with dietary nitrate?
Yes. NITRATE-IQ™’s three-protocol adjustable dosing lets you run cardiovascular and performance tracking from a single supplement. The Cardiovascular protocol (270 mg NO₃⁻, 6 caps daily) sits at the lower end of the Kapil et al. (2015) dose (roughly 6.4 mmol/day) for morning BP monitoring: set a baseline, run 8 weeks, and track your own SBP/DBP trend. That dose is a reference for your input level, not a predicted result for you; Kapil was run in hypertensive, mostly medicated patients using beetroot juice.
For a healthy-population reference, a spinach RCT at 845 mg/day for 7 days reported a central systolic reduction of 3.39 mmHg (Jovanovski et al., 2015). The Performance protocol (540 mg NO₃⁻, about 8.7 mmol, 12 caps taken 2 to 3 hours pre-effort) exceeds the ≥6 mmol/day threshold identified by Poon et al. (2025), who found improvements in time to exhaustion but no improvement in time-trial performance, VO₂max, or strength. HRV captures systemic recovery; resting heart rate captures cardiovascular adaptation.
Enovita™ at 150 mg or 300 mg adds an enzymatic NO pathway variable, with the eNOS mechanism characterized in cell culture by Schön et al. (2021), whose human blood-pressure endpoint was not met. Run a 2-week baseline at 135 mg before escalating, so you have within-subject comparison data. Dietary nitrate supports nitric oxide production, which helps maintain healthy blood pressure already within the normal range.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
How do salivary test strips work, and do they confirm my supplement is working?
Salivary test strips read salivary nitrite, the product of oral bacterial reduction of nitrate in the enterosalivary circuit, where plasma nitrate is concentrated in saliva at roughly a 10:1 ratio. A positive reading indicates the dietary nitrate you ingested is engaging the bacterial conversion step rather than transiting unreduced. Protocol: take strips 2 to 3 hours after dosing, matching the plasma nitrite peak reported by Wylie et al. (2013), and skip antiseptic mouthwash for the 2 hours before. A negative reading can flag mouthwash interference, a depleted oral bacterial population, or an insufficient dose. With NITRATE-IQ™’s labeled-milligram dosing supplying the input variable (270 mg NO₃⁻ at the Cardiovascular protocol), the strips close the loop: input dose known, conversion confirmed. Strips confirm a conversion step is occurring; they do not measure blood pressure, performance, or any clinical outcome.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
Your Experimental Design Questions, Answered
Why have I been unable to find a dietary nitrate supplement with labeled milligrams of NO₃⁻?
Much of the industry standardizes to extract weight rather than active NO₃⁻ content, mostly because standardizing to a specific NO₃⁻ percentage means running ion chromatography on every inbound batch, it creates labeling accountability, and it costs more than ratio-based concentration. Gallardo and Coggan (2019) documented the result: across 24 commercial beetroot-juice products, nitrate content spanned close to a 50-fold range, only five consistently delivered ≥5 mmol (about 310 mg) per serving, and lots of the same product varied by an average of 30%. NITRATE-IQ™ uses Nitrate Burst™ spinach extract standardized to 9% NO₃⁻, verified by ion chromatography on every batch, which is what makes the milligram declaration on the label possible.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
How do I choose between the Daily Primer, Cardiovascular, and Performance protocols?
Start with the Daily Primer (3 caps, 135 mg) for 2 weeks as a within-subject baseline at a deliberately sub-threshold dose. Move to the Cardiovascular protocol (6 caps, 270 mg) for morning BP tracking, near the lower end of the Kapil et al. (2015) dose. Use the Performance protocol (12 caps, 540 mg, taken 2 to 3 hours pre-effort) for exercise-benchmark tracking, it is the only tier above the ≥6 mmol/day threshold identified by Poon et al. (2025). Norouzzadeh et al. (2024) found effects are dose- and duration-dependent, so the step-escalation design gives you within-subject dose-response data that beats a simple pre-post comparison. Note that the 270 mg and 540 mg protocols exceed the EFSA/JECFA acceptable daily intake for nitrate (3.7 mg/kg body weight/day, about 260 mg for a 70 kg adult); discuss long protocols with your healthcare provider.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
What should I document to make my n=1 data shareable and reproducible?
At minimum: product name, labeled mg NO₃⁻ per serving, batch number, and COA date; the protocol tier you used (135/270/540 mg); dosing time relative to sleep and meals; your mouthwash-avoidance protocol; baseline period duration; primary endpoint device and protocol (BP cuff model, measurement time, arm, three-reading average); secondary endpoint devices; and confound logging (sleep quality, dietary nitrate from food, alcohol, stress). With a defined independent variable, your documentation is complete enough for other experimenters to replicate.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
For the Precision Researcher: Complete Methodology and Ingredient Documentation
Before You Start
Potassium-related caution: Because of the potassium content (195 to 780 mg per protocol), talk to your healthcare provider first if you take potassium-sparing diuretics, ACE inhibitors, or ARBs.
Nitrate-related caution, important: Do not combine dietary nitrate with organic nitrate medications (nitroglycerin, isosorbide) or PDE-5 inhibitors (sildenafil, tadalafil) without medical supervision. The combination can cause an additive drop in blood pressure. This risk comes from the nitrate, not the potassium.
Intake context: The internationally used acceptable daily intake for nitrate is 3.7 mg per kg body weight per day, about 260 mg daily for a 70 kg adult (EFSA/JECFA). The 270 mg and 540 mg protocols exceed that reference intake. The ADI is a lifetime-average food-additive benchmark rather than an acute safety limit, and clinical trials have used comparable or higher doses short-term, but long protocols warrant a conversation with your healthcare provider.
Exclusions: Not for use by anyone who is pregnant or nursing, or under 18 years of age.
Space medications 1 to 2 hours before or after dosing.
Full Ingredient Technical Profiles
Nitrate Burst™ Spinach Extract (Spinacia oleracea), 1,500 / 3,000 / 6,000 mg at 3 / 6 / 12 caps
Dual-standardized to 9% dietary nitrate (NO₃⁻) and 13% naturally co-occurring potassium (K⁺). NO₃⁻ is quantified by ion chromatography on every inbound batch; K⁺ is quantified by flame photometry or ICP-OES. The two markers require different methods, flame photometry measures alkali metals by emission and cannot quantify the nitrate anion. Both markers are declared on the Supplement Facts panel.
Beet-free by design: the spinach source delivers the NO₃⁻ ion with no betalain pigment (no beeturia regardless of dose), no beet sugars, and no beet taste. On the evidence for non-beet sources: Jędrejko et al. (2024) is a narrative review of 11 human publications on alternative nitrate sources, of which eight used red spinach (Amaranthus species, including A. dubius and A. hypochondriacus) and only three used green spinach (Spinacia oleracea), with mixed results across trials: two A. dubius trials reported an increased ventilatory threshold with no significant change in time to exhaustion or VO₂peak, while others measured anaerobic power endpoints with inconsistent outcomes. Amaranthus is a different genus from the Spinacia oleracea in Nitrate Burst™.
The botanically matched evidence is Jovanovski et al. (2015), a placebo-controlled crossover trial in 27 healthy adults using Spinacia oleracea soup at 845 mg nitrate/day versus asparagus soup for 7 days, which reported central systolic blood pressure 3.39 ± 5.6 mmHg lower on the high-nitrate arm (p = 0.004, measured 180 minutes post-consumption); the between-arm arterial-stiffness difference at Day 7 was not statistically significant.
Anti-doping note: dietary nitrate does not appear on the WADA Prohibited List (2026 List, in force since 1 January 2026). NITRATE-IQ™ is not currently NSF Certified for Sport. Competitive athletes subject to testing should check with their governing body before use.
Enovita™ Grape-Seed Extract, 75 / 150 / 300 mg at 3 / 6 / 12 caps
Produced by Indena S.p.A. under cGMP; the extract is manufactured in Tours, France, using water as the only extraction solvent (no ethanol, no acetone, no organic solvent residues), with clinical tablets prepared by Indena S.p.A. in Milan, Italy. The specification reported in Schön et al. (2021) is ≥95% total proanthocyanidins with a 5 to 15% flavane monomer fraction (catechin and epicatechin), from grape seeds sourced as a white-wine production byproduct. Specifications differ by source and lot: the material characterized in Belcaro et al. (2013) was reported at approximately 91% OPCs with about 8.6% monomers, and HumanN’s Cardio Daily lists Enovita™ at 85% OPCs.
Two branded human studies are associated with the ingredient. Schön et al. (2021) combined in-vitro endothelial cell work, which characterized activating eNOS phosphorylation, reduced endothelin-1 and sICAM secretion, and increased sVCAM secretion, with a clinical arm whose primary blood-pressure endpoint was not met. Belcaro et al. (2013) was a four-month open, non-randomized registry study of 119 adults at 150 mg/day and 300 mg/day. The in-vitro work is what documents the eNOS mechanism; the human studies are cited as dose references, not as proof of a blood-pressure benefit. For the ingredient class more broadly, a meta-analysis of 16 randomized trials in 810 participants reported a systolic reduction of 6.08 mmHg with generic grape seed extract (Zhang et al., 2016), class-level evidence, not evidence for the branded material.
Natural Potassium (K⁺), 195 / 390 / 780 mg at 3 / 6 / 12 caps
Naturally co-occurring from the Nitrate Burst™ spinach matrix at 13% by weight, not an isolated mineral salt addition. It activates BKCa channels in vascular smooth muscle (NO-independent) and supports normal natriuresis, both mechanisms discussed in Houston and Harper (2008). A dose-response meta-analysis of randomized trials found the potassium-blood-pressure relationship is U-shaped, weakens above roughly 30 mmol/day of intake difference, and is concentrated in people with hypertension and higher sodium intake (Filippini et al., 2020, pooling 32 randomized trials at supplementation doses of 30 to 140 mmol/day). That analysis also found blood pressure increased above intake differences of roughly 80 mmol/day, most notably in people on antihypertensive medication, another reason NITRATE-IQ™’s comparatively small potassium doses are described mechanistically rather than as an outcome promise. At the 12-cap Performance tier: 780 mg, or 17% DV, a good source of potassium; the 195 mg (4% DV) and 390 mg (8% DV) tiers do not reach the ≥10% DV good-source threshold. Potassium contributes to normal vascular smooth-muscle function.* NITRATE-IQ™ makes a structure/function statement here rather than the FDAMA potassium and blood-pressure health claim.
Fulvic Acid, 30 / 60 / 120 mg at 3 / 6 / 12 caps
Purified fulvic acid. Lead, arsenic, mercury, and cadmium are tested by ICP-MS on every batch, with results below California Proposition 65 Safe Harbor levels (MADL/NSRL) and within USP heavy-metal limits.
Fulvic acid is included as a formulation component, not as an active we make claims for. In animal toxicology studies, fulvic acid showed no genotoxicity and no acute oral toxicity at the maximum tested dose of 5,000 mg/kg body weight/day (Dai et al., 2020; the 60-day no-observed-adverse-effect level was also 5,000 mg/kg/day, the highest dose tested). That study used rodents and in-vitro assays, and the tested material differs in purity and source from our raw material, so it is safety context rather than an efficacy basis. It was also published in the same journal noted above as delisted in 2023 and discontinued in 2024, a further reason we treat it as supporting context rather than as a substantiation basis. We have preclinical safety data for it and no human efficacy evidence, so we are not claiming a benefit from it.
The 16-Week Precision Health Protocol
Phase 1: Baseline Establishment (Weeks 1 to 2) Protocol: 3-cap Daily Primer (135 mg NO₃⁻ / 75 mg Enovita™ / 195 mg K⁺) daily. Documentation: morning BP (three-reading average, same arm, same device, same time); nightly HRV average; resting HR; a salivary test strip at Week 1, Day 7 (2 to 3 hours post-dose, no mouthwash prior). Purpose: generate within-subject low-dose baseline data. Norouzzadeh et al. (2024) found duration-dependent effects, so this period becomes the comparison reference for your escalation deltas.
Phase 2: Cardiovascular Experiment (Weeks 3 to 10) Protocol: 6-cap Cardiovascular (270 mg NO₃⁻ / 150 mg Enovita™ / 390 mg K⁺) daily. Documentation: all Phase 1 endpoints continued daily; weekly averages calculated; salivary test strip at Week 3, Day 7. Primary analysis: SBP/DBP weekly-average delta versus Phase 1 baseline. Your dose sits below the roughly 6.4 mmol/day used in Kapil et al. (2015), and that trial’s population was hypertensive and mostly medicated, so treat it as a dose reference, not a predicted outcome. Secondary: HRV trend delta; resting HR delta; subjective energy and recovery score.
Phase 3: Performance Experiment (Weeks 11 to 16) Protocol: 12-cap Performance (540 mg NO₃⁻ / 300 mg Enovita™ / 780 mg K⁺) on training days, taken 2 to 3 hours pre-effort to align with the plasma nitrite peak reported by Wylie et al. (2013); 3-cap Daily Primer on rest days for chronic loading (Poon et al. found chronic supplementation beyond 3 days produced greater time-to-exhaustion improvements than acute dosing). Documentation: pre/post submaximal benchmark test; RPE at matched intensities; power-to-HR ratio. Primary analysis: benchmark delta versus Phase 1 baseline. Set expectations against what Poon et al. actually found, improvements in time to exhaustion, but no improvement in time-trial performance, VO₂max, or strength.
Confound Control Throughout All Phases Mouthwash: no antiseptic (chlorhexidine, cetylpyridinium chloride) within 2 hours of dosing; regular fluoride toothpaste is not expected to affect nitrate-reducing oral bacteria. Dietary background: log major dietary nitrate sources (leafy greens, beets) daily during Phases 2 and 3, since a stable background reduces noise. Medications: see the “Before You Start” cautions above, potassium-related and nitrate-related interactions are separate issues with separate mechanisms.
Extended FAQ
What is the antiseptic mouthwash interaction, and how do I control for it?
Antiseptic mouthwash compounds (chlorhexidine, cetylpyridinium chloride) kill the oral bacteria, mainly Neisseria, Veillonella, and Actinomyces species, that reduce salivary nitrate to nitrite in the enterosalivary circuit. Without that bacterial conversion, the substrate pathway’s NO production drops, so antiseptic mouthwash within the 2 hours before dosing is a major confound. Control it: log mouthwash use, avoid antiseptic mouthwash within 2 hours of dosing, and use regular fluoride toothpaste instead. If your strips come back negative despite a known labeled dose, check for mouthwash use before you blame the conversion.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
Can I combine NITRATE-IQ™ with my existing L-Citrulline stack?
Yes, and the design stays interpretable because the two inputs are mechanistically distinct. L-Citrulline targets the enzymatic eNOS pathway by raising plasma L-arginine; NITRATE-IQ™’s dietary nitrate targets the NOS-independent enterosalivary pathway, two separate upstream routes into the same downstream NO cascade. We’re not claiming the combination is additive in effect; no co-supplementation trial is cited here for that. For your design, your dietary nitrate variable stays defined and isolated, and L-Citrulline adds a second, separately logged variable. Tracking both inputs lets you attribute changes to one or the other rather than to an undifferentiated stack.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
What does the Enovita™ eNOS mechanism mean in practice for biomarker tracking?
Activating phosphorylation of eNOS is the molecular event that raises the constitutive NO production rate of endothelial cells. In cell culture, Enovita™ increased phosphorylated eNOS by about 45% within 5 minutes (Schön et al., 2021); cell-culture findings do not establish an effect in people, and that study’s human blood-pressure endpoint was not met. For tracking purposes, the Enovita™ dose variable (75/150/300 mg) is separable from the NO₃⁻ dose (135/270/540 mg). If you want to isolate Enovita™’s contribution, hold the NO₃⁻ dose constant and vary Enovita™ over time, though the stepped protocol gives you useful dose-response context without that.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
How long before measurable changes appear in cardiovascular biomarkers?
Kapil et al. (2015) measured primary endpoints at 4 weeks, and Norouzzadeh et al. (2024) found duration-dependent effects over longer protocols. For a morning BP trend, the most interpretable data tends to arrive around Week 8. Acute plasma nitrite rises within about 2 to 3 hours of dosing (Wylie et al., 2013), but home BP monitoring reflects slower changes that build over weeks. HRV varies substantially between individuals; trends usually emerge over 4 to 6 weeks of consistent tracking. For exercise benchmarks, Poon et al. (2025) found chronic dosing beyond 3 days outperformed acute single doses, so a 2-week loading phase before benchmark testing gives cleaner data. Note that some well-conducted randomized trials in populations with elevated and mildly elevated blood pressure found no blood-pressure change at all, so a flat trend is a legitimate result, not a protocol failure.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
What confounds should I control for in a dietary nitrate biomarker experiment?
The primary ones: (1) antiseptic mouthwash, which kills the oral bacteria central to NO₃⁻ to NO₂⁻ conversion, so avoid it within 2 hours of dosing and log any use; (2) dietary nitrate from food, since leafy greens and other high-nitrate vegetables add to the substrate pool; (3) training load, which acutely moves both BP and HRV; (4) sleep quality; (5) alcohol, which suppresses HRV and modulates BP; and (6) sodium intake, which affects BP interpretation. With a defined primary input, these secondary confounds become manageable logging tasks rather than experiment-invalidating unknowns.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
What is a well-designed dietary nitrate tracking protocol, start to finish?
A three-phase protocol:
Phase 1 (Baseline, Weeks 1 to 2): 3-cap Daily Primer (135 mg NO₃⁻, batch-verified by ion chromatography); record morning BP (three-reading average), resting HR, and nightly HRV, and take a salivary test strip 2 to 3 hours post-dose to establish baseline conversion.
Phase 2 (Cardiovascular, Weeks 3 to 10): escalate to the 6-cap Cardiovascular protocol (270 mg NO₃⁻); continue daily monitoring; document weekly averages. Reference the Kapil et al. (2015) dose (roughly 6.4 mmol/day) as an input comparison only, that trial studied hypertensive, mostly medicated patients using beetroot juice, and the dose- and duration-dependent effects reported by Norouzzadeh et al. (2024).
Phase 3 (Performance, Weeks 11 to 16): on training days, shift to the 12-cap Performance protocol (540 mg NO₃⁻, about 8.7 mmol) taken 2 to 3 hours pre-effort per Wylie et al. (2013), holding the 3-cap Daily Primer on rest days for chronic loading; track submaximal benchmarks, with the caveat that Poon et al. (2025) found gains in time to exhaustion but none in time-trial performance, VO₂max, or strength.
Confound controls throughout: antiseptic mouthwash avoidance for 2 hours pre-dose, stable dietary-background logging, sleep quality, and training load.
Before starting: the 270 mg and 540 mg protocols exceed the EFSA/JECFA nitrate acceptable daily intake (3.7 mg/kg/day, about 260 mg for a 70 kg adult), this product is not for anyone pregnant, nursing, or under 18, and dietary nitrate should not be combined with organic nitrate medications or PDE-5 inhibitors without medical supervision.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
The Experiment Is Now Controlled
You’ve been running the right experiment with an undefined variable. The tracking column now has a number. The dose can be compared to published research. The two-layer verification, labeled input plus salivary strip conversion confirmation, closes a loop most prior dietary nitrate supplements left open.
NITRATE-IQ™ supports nitric oxide production and vascular biomarker tracking, with its 135/270/540 mg NO₃⁻ protocols set as defined, COA-verified doses you can reference against published dietary nitrate research, including the Kapil et al. (2015) dose (roughly 6.4 mmol/day, studied in hypertensive patients, most on blood-pressure medication, using beetroot juice) and the Poon et al. (2025) umbrella review on exercise performance. Those studies are dose references, not NITRATE-IQ™, and their results are not a predicted or expected outcome of taking this product.*
NITRATE-IQ™ declares its nitrate content in milligrams per serving, batch-verified by ion chromatography.* 135/270/540 mg NO₃⁻, documented on a Certificate of Analysis, referenced against published dosing ranges.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
Triquetra Health, as of [MONTH YEAR]: Top 500 Amazon seller, over 2 million customers served, 32,600+ five-star reviews out of [TOTAL] total reviews averaging [X.X] stars, and 1,500+ clinician relationships.
Start the experiment:
Learn More About NITRATE-IQ™ →
Backed by Triquetra Health’s 90-day money-back guarantee, see terms. Nitrate Burst™ and Enovita™ are manufactured in cGMP-certified facilities, with identity, potency, and heavy-metal testing documented on a batch Certificate of Analysis.
NITRATE-IQ™ is likely to be relevant for:
- Biohackers and precision health consumers running controlled dietary nitrate experiments that need a defined, batch-verified input traceable to published dosing ranges
- Supplement evaluators who’ve disqualified products on the basis of undefined dose, proprietary blend, extract weight, or no labeled mg NO₃⁻
- Multi-biomarker trackers who need a supplement input that’s defined, consistent, and batch-documented
- Healthcare practitioners who want a Supplement Facts panel they can evaluate against published research before counseling a client
- Anyone tracking the dietary nitrate to plasma nitrite to vascular NO cascade, which calls for test strip compatibility alongside a labeled input dose
- Dose-escalation designs that need defined, adjustable doses to generate within-subject dose-response data
NITRATE-IQ™ may not be the priority when someone isn’t actively tracking biomarkers; when budget constraints make it hard to justify relative to high-nitrate foods; or when a competitive context requires third-party certification the product does not currently hold (consult your governing body’s anti-doping advisor).
Scientific References & Citations
Alphabetized. All sources are independently verifiable through the identifiers below.
Bailey, S. J., Winyard, P., Vanhatalo, A., Blackwell, J. R., DiMenna, F. J., Wilkerson, D. P., Tarr, J., Benjamin, N., & Jones, A. M. (2009). Dietary nitrate supplementation reduces the O₂ cost of low-intensity exercise and enhances tolerance to high-intensity exercise in humans. Journal of Applied Physiology, 107(4), 1144–1155. https://doi.org/10.1152/japplphysiol.00722.2009
Belcaro, G., Ledda, A., Hu, S., Cesarone, M. R., Feragalli, B., & Dugall, M. (2013). Grape seed procyanidins in pre- and mild hypertension: A registry study. Evidence-Based Complementary and Alternative Medicine, 2013, 313142. https://doi.org/10.1155/2013/313142
Blekkenhorst, L. C., Lewis, J. R., Prince, R. L., Devine, A., Bondonno, N. P., Bondonno, C. P., Wood, L. G., Puddey, I. B., Ward, N. C., Croft, K. D., Woodman, R. J., Beilin, L. J., & Hodgson, J. M. (2018). Nitrate-rich vegetables do not lower blood pressure in individuals with mildly elevated blood pressure: A 4-wk randomized controlled crossover trial. The American Journal of Clinical Nutrition, 107(6), 894–908. https://doi.org/10.1093/ajcn/nqy061
Dai, C., Xiao, X., Yuan, Y., Sharma, G., & Tang, S. (2020). A comprehensive toxicological assessment of fulvic acid. Evidence-Based Complementary and Alternative Medicine, 2020, 8899244. https://doi.org/10.1155/2020/8899244
Filippini, T., Naska, A., Kasdagli, M.-I., Torres, D., Lopes, C., Carvalho, C., Moreira, P., Malavolti, M., Orsini, N., Whelton, P. K., & Vinceti, M. (2020). Potassium intake and blood pressure: A dose-response meta-analysis of randomized controlled trials. Journal of the American Heart Association, 9(12), e015719. https://doi.org/10.1161/JAHA.119.015719
Gallardo, E. J., & Coggan, A. R. (2019). What’s in your beet juice? Nitrate and nitrite content of beet juice products marketed to athletes. International Journal of Sport Nutrition and Exercise Metabolism, 29(4), 345–349. https://doi.org/10.1123/ijsnem.2018-0223
Gao, C., Gupta, S., Adli, T., Hou, W., Coolsaet, R., Hayes, A., Kim, K., Pandey, A., Gordon, J., Chahil, G., Belley-Cote, E. P., & Whitlock, R. P. (2021). The effects of dietary nitrate supplementation on endurance exercise performance and cardiorespiratory measures in healthy adults: A systematic review and meta-analysis. Journal of the International Society of Sports Nutrition, 18(1), 55. https://doi.org/10.1186/s12970-021-00450-4
Houston, M. C., & Harper, K. J. (2008). Potassium, magnesium, and calcium: Their role in both the cause and treatment of hypertension. The Journal of Clinical Hypertension, 10(7 Suppl 2), 3–11. https://doi.org/10.1111/j.1751-7176.2008.08575.x
Hyde, E. R., Andrade, F., Vaksman, Z., Parthasarathy, K., Jiang, H., Parthasarathy, D. K., Torregrossa, A. C., Tribble, G., Kaplan, H. B., Petrosino, J. F., & Bryan, N. S. (2014). Metagenomic analysis of nitrate-reducing bacteria in the oral cavity: Implications for nitric oxide homeostasis. PLoS ONE, 9(3), e88645. https://doi.org/10.1371/journal.pone.0088645
Jędrejko, M., Jędrejko, K., Gómez-Renaud, V. M., Kała, K., & Muszyńska, B. (2024). Exploring the impact of alternative sources of dietary nitrate supplementation on exercise performance. International Journal of Molecular Sciences, 25(7), 3650. https://doi.org/10.3390/ijms25073650
Jovanovski, E., Bosco, L., Khan, K., Au-Yeung, F., Ho, H., Zurbau, A., Jenkins, A. L., & Vuksan, V. (2015). Effect of spinach, a high dietary nitrate source, on arterial stiffness and related hemodynamic measures: A randomized, controlled trial in healthy adults. Clinical Nutrition Research, 4(3), 160–167. https://doi.org/10.7762/cnr.2015.4.3.160
Kapil, V., Khambata, R. S., Robertson, A., Caulfield, M. J., & Ahluwalia, A. (2015). Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: A randomized, phase 2, double-blind, placebo-controlled study. Hypertension, 65(2), 320–327. https://doi.org/10.1161/HYPERTENSIONAHA.114.04675
Lundberg, J. O., Weitzberg, E., & Gladwin, M. T. (2008). The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. Nature Reviews Drug Discovery, 7(2), 156–167. https://doi.org/10.1038/nrd2466
Norouzzadeh, M., Hasan Rashedi, M., Payandeh, N., Mirdar Harijani, A., & Shahinfar, H. (2024). The effects of dietary nitrate on blood pressure and vascular health: An umbrella review and updated meta-analysis and meta-regression. Journal of Functional Foods, 114, 106082. https://doi.org/10.1016/j.jff.2024.106082
Poon, E. T.-C., Iu, J. C.-K., Sum, W. M.-K., Wong, P.-S., Lo, K. K.-H., Ali, A., Burns, S. F., & Trexler, E. T. (2025). Dietary nitrate supplementation and exercise performance: An umbrella review of 20 published systematic reviews with meta-analyses. Sports Medicine, 55(5), 1213–1231. https://doi.org/10.1007/s40279-025-02194-6
Schön, C., Allegrini, P., Engelhart-Jentzsch, K., Riva, A., & Petrangolini, G. (2021). Grape seed extract positively modulates blood pressure and perceived stress: A randomized, double-blind, placebo-controlled study in healthy volunteers. Nutrients, 13(2), 654. https://doi.org/10.3390/nu13020654
Seals, D. R., Jablonski, K. L., & Donato, A. J. (2011). Aging and vascular endothelial function in humans. Clinical Science, 120(9), 357–375. https://doi.org/10.1042/CS20100476
Sundqvist, M. L., Larsen, F. J., Carlström, M., Bottai, M., Pernow, J., Hellénius, M.-L., Weitzberg, E., & Lundberg, J. O. (2020). A randomized clinical trial of the effects of leafy green vegetables and inorganic nitrate on blood pressure. The American Journal of Clinical Nutrition, 111(4), 749–756. https://doi.org/10.1093/ajcn/nqaa024
U.S. Food and Drug Administration. (2000, October 31). Health claim notification for potassium containing foods (Docket No. 2000Q-1582). https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/health-claim-notification-potassium-containing-foods
Wylie, L. J., Kelly, J., Bailey, S. J., Blackwell, J. R., Skiba, P. F., Winyard, P. G., Jeukendrup, A. E., Vanhatalo, A., & Jones, A. M. (2013). Beetroot juice and exercise: Pharmacodynamic and dose-response relationships. Journal of Applied Physiology, 115(3), 325–336. https://doi.org/10.1152/japplphysiol.00372.2013
Zhang, H., Liu, S., Li, L., Liu, S., Liu, S., Mi, J., & Tian, G. (2016). The impact of grape seed extract treatment on blood pressure changes: A meta-analysis of 16 randomized controlled trials. Medicine, 95(33), e4247. https://doi.org/10.1097/MD.0000000000004247
Evidence hierarchy: Umbrella reviews of systematic reviews with meta-analyses (Poon et al., 2025, performance; Norouzzadeh et al., 2024, cardiovascular). Meta-analyses of randomized trials (Gao et al., 2021; Filippini et al., 2020; Zhang et al., 2016, generic grape seed extract, not Enovita™). Randomized controlled trials (Kapil et al., 2015, hypertensive population; Jovanovski et al., 2015, healthy population; Wylie et al., 2013; Bailey et al., 2009; Sundqvist et al., 2020, null; Blekkenhorst et al., 2018, null). Randomized controlled trial with a null primary endpoint, cited for in-vitro mechanism only (Schön et al., 2021). Narrative review (Jędrejko et al., 2024). Open registry study, not randomized or blinded (Belcaro et al., 2013). Laboratory product-composition analysis, not clinical evidence (Gallardo & Coggan, 2019). Preclinical rodent and in-vitro safety data only (Dai et al., 2020). Mechanistic reference reviews (Lundberg et al., 2008; Hyde et al., 2014; Seals et al., 2011).
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
Cardiovascular and performance statements referencing published research describe population-level effects observed at specified dose ranges in study populations that are not identical to NITRATE-IQ™ users, using products that are not NITRATE-IQ™. Individual responses vary based on baseline cardiovascular status, oral microbiome composition, dietary background, training status, and other biological factors. Home biomarker monitoring provides individual trend data; it does not constitute a clinical diagnosis or medical evaluation. Consult your healthcare provider for interpretation of cardiovascular data and before making changes to any existing health protocol or medication regimen.